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Abstract 
Parkinson’s disease (PD) is characterized by resting tremor, rigidity, and bradykinesia. 
Dopaminergic medications treat motor symptoms, but have complex effects on cognition, 
including impulse control. Impulsivity is multifaceted in nature. Motor impulsivity involves 
inability to withhold prepotent, automatic responses whereas cognitive impulsivity refers to 
increased risk-taking and reward-seeking. We anticipated that dopaminergic therapy would 
decrease motor impulsivity. We employed the Go/No-go paradigm to assess motor 
impulsivity. PD patients were tested on and off their dopaminergic medication. PD patients 
on medication had a significantly higher proportion of Go Timeouts (i.e., Go responses not 
completed by the 750 millisecond deadline) compared to off medication (p=0.01). We 
interpret that dopaminergic therapy induces more conservative responding (i.e., decreased 
motor impulsivity) in PD patients. This contrasts with the widely-recognized notion of 
dopaminergic therapy increasing cognitive impulsivity and risk of impulse control disorders. 
Understanding the nuanced effects of dopaminergic treatment in PD will inform clinical 
decisions.  
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Chapter 1 : Introduction 
A version of subsections 1.4.2 and 1.5 of this chapter has been published (Yang, Lauzon, 
Seergobin, & MacDonald, 2018). 
1.1 Parkinson’s disease 
1.1.1 Symptomatology 
Parkinson’s disease (PD) is a progressive and incurable neurodegenerative disorder. Risk 
of PD increases with age; prevalence of the disease worldwide is 428 per 100 000 
individuals aged 60-69, 1087 per 100 000 individuals aged 70-79, and 1903 per 100 000 
individuals aged 80+ (Pringsheim, Jette, Frolkis, & Steeves, 2014). It is the 
neurodegenerative disorder with the second highest prevalence, behind only Alzheimer’s 
disease (de Lau & Breteler, 2006). Symptoms of PD typically arise in older age, with 
average PD age-of-onset of 65 years old, with a smaller number of early-onset PD 
patients (Connolly & Lang, 2014). The disease primarily affects motor functioning, with 
the cardinal symptoms of PD being resting tremor, rigidity, and bradykinesia (Jankovic, 
2008). Resting tremor refers to a tremor in various areas of the body, commonly the 
limbs, that occurs at rest but dissipates or even disappears with the assumption of posture 
or with deliberate movement (Jankovic, 2008). Patients with PD often experience a 
phenomenon called cogwheel rigidity in the upper limbs (Jankovic, 2008). When the 
forearm is passively extended at the elbow, intermittent resistance can be felt that 
resembles ratcheting, or ‘cogwheeling’. Bradykinesia is the presence of slowed 
movements (Jankovic, 2008). A unique feature of PD symptomology is unilateral onset 
of motor symptoms and asymmetry of motor impairments that persist throughout the 
disease course (Dickson, 2012). The asymmetry of symptoms is not observed in multiple 
systems atrophy and progressive supranuclear palsy that are diseases under the 
parkinsonism umbrella, helping with diagnosis, though corticobasal ganglionic 
degeneration and Lewy body dementia can present asymmetrically (Dickson, 2012). In 
addition to motor symptoms, PD diagnosis is commonly associated with subtle cognitive 
dysfunction that might not necessarily reduce daily function (Aarsland, Brønnick, & 
Fladby, 2011; Litvan et al., 2012). As PD progresses, motor function becomes 
3 
 
increasingly impaired and the risk of developing motor complications such as dyskinesias 
increases (Coelho & Ferreira, 2012; Kalia & Lang, 2015). In late stage PD, patients also 
experience disruptions in cognition, gait/balance, and autonomic function (Coelho & 
Ferreira, 2012; Kalia & Lang, 2015). Unfortunately, there is no cure for Parkinson’s 
disease at present.  
1.1.2 Dopaminergic system 
The principal neurotransmitter system impacted by PD is the dopaminergic system. The 
main dopamine-producing neurons are found in the substantia nigra pars compacta (SNc) 
and the ventral tegmental area (VTA), both located in the midbrain. The striatum receives 
significant investment of dopaminergic projections and is the input region of the basal 
ganglia, a collection of sub-cortical nuclei (Meyer & Quenzer, 2013). The striatum is 
commonly conceptually divided into dorsal and ventral components (i.e., DS and VS, 
respectively) based on differences in function, dopaminergic inputs, and glutamatergic 
projections from cortex (Voorn, Vanderschuren, Groenewegen, Robbins, & Pennartz, 
2004). DS is comprised of the bulk of the caudate nuclei and putamen, whereas VS 
includes the nucleus accumbens (NAcc) and the most ventral aspects of the caudate and 
putamen (Voorn et al., 2004). The striatum is also divided histochemically into 
striosomes, which are labyrinth-like structures containing 10-15% of striatal volume, and 
the matrix, which comprises the remaining majority of striatal volume (Brimblecombe & 
Cragg, 2017). The dopaminergic system consists of three primary pathways (see Figure 
1): the nigrostriatal, mesolimbic, and mesocortical pathways (Meyer & Quenzer, 2013). 
The nigrostriatal pathway originates in the SNc and projects to the DS (Meyer & 
Quenzer, 2013). The mesolimbic and mesocortical pathways originate in the VTA and 
innervate a) the VS, hippocampus, and mediotemporal regions, versus b) the prefrontal 
cortex, respectively (Meyer & Quenzer, 2013).  
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Figure 1. Major dopaminergic brain regions and dopamine pathways in the brain.  
Ernst, M. & Luciana, M. (2015). Neuroimaging of the dopamine/reward system in adolescent drug use. 
CNS Spectrums, 20(4), 427-441. Reproduced with permission. © Cambridge University Press 2015. 
Dopamine secreted by the SNc and VTA bind to and activate dopamine receptors located 
on medium spiny neurons (MSNs) throughout the striosomes and matrix of the striatum 
(Bolam, Hanley, Booth, & Bevan, 2000). Dopamine receptors, which are G-protein 
coupled receptors, are loosely divided into D1-like and D2-like receptors. D1-like 
receptors (i.e., D1, D5) couple to Gs stimulatory G proteins to induce downstream 
activation, whereas D2-like receptors (i.e., D2, D3, D4) cause inhibition by coupling to 
Gi inhibitory G proteins (Jaber, Robinson, Missale, & Caron, 1996). D1-like receptors are 
largely found within striosome structures and D2-like receptors are richly expressed in 
the striatal matrix (Brimblecombe & Cragg, 2017). The two types of dopamine receptors 
contribute to the direct and indirect pathways of the basal ganglia (see Figure 2). 
Engagement of the direct pathway results in overall increased activation of the cortical 
region to which the striatal segment projects (Purves et al., 2001). The indirect pathway 
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dampens the activation of the direct pathway through inhibitory connections to the 
external segment of the globus pallidus and subthalamic nucleus (Purves et al., 2001). As 
such, engagement of the indirect pathway leads to decreased thalamic and cortical 
activation (Purves et al., 2001). Collectively, these two pathways constitute a fine-tuned 
and highly-precise system for coordinating complex cortical networks that underlies 
functions such as motor movements. 
 
Figure 2. Direct and indirect pathways of the basal ganglia.  
Leisman, G., Melillo, R., & Carrick, F. R. (2012). Clinical motor and cognitive neurobehavioral 
relationships in the basal ganglia. In C. Bauer (Ed.), Basal ganglia - An integrative view (pp. 1-30). 
London, UK: IntechOpen Limited. Reproduced with permission. © 2012 Leisman et al., licensee InTech. 
DA synaptic signaling is regulated by the activity of dopamine transporter (DAT), which 
engages in the reuptake of dopamine back into the presynaptic nerve terminal or into 
surrounding glia (Purves et al., 2001). DAT is a sodium-dependent transporter and can be 
located on presynaptic MSNs throughout the striatum (Chen & Reith, 2000; van Dyck et 
al., 2002). After reuptake, dopamine is metabolized by catechol O-methyltransferase 
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(COMT), which is a cytoplasmic enzyme, and monoamine oxidase (MAO), which is 
located on the outer mitochondrial membrane (Purves et al., 2001). These dopamine-
degrading enzymes can be found in striatal neurons as well as associated glial cells 
(Purves et al., 2001).  
1.1.3 PD neuropathology 
The central neuropathology in PD is the degradation of the SNc, a dopamine-producing 
subregion of the SN (Dauer & Przedborski, 2003). This neurodegeneration results in 
disruption to the nigrostriatal pathway and dopamine deficiency in the DS (Meyer & 
Quenzer, 2013), giving rise to the hallmark motor symptoms of PD (Dickson et al., 
2009). In normal brains, slices of the midbrain show a visible dark band along the SNc 
(see Figure 3A). This is attributed to neuromelanin pigmentation found in dopaminergic 
neurons of the SNc (Dauer & Przedborski, 2003). The nigrostriatal pathway is intact and 
appropriately supplies the caudate and putamen with dopamine. However, the 
pigmentation along the SNc ridge in midbrain slices of PD patients is greatly reduced 
because of the loss of dopaminergic neurons and the associated production of 
neuromelanin (see Figure 3B). The degeneration of SNc neurons is extensive; by the 
time PD patients exhibit clinical symptoms, approximately 60% of neurons in the SNc 
have already been lost and dopamine supply to the putamen is reduced by approximately 
80% (Dauer & Przedborski, 2003). Neurodegeneration can also be detected in other brain 
regions in PD, including the locus ceruleus, amygdala, and hypothalamus (Dickson, 
2012).  
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Figure 3. Neuropathology of PD. 
A) Schematic of a normal brain. The SNc is clearly visible as a darker pigmented line in the midbrain due 
to neuromelanin produced in dopaminergic neurons. The nigrostriatal pathway is intact and supplies 
dopamine to the caudate and putamen. B) Schematic of a PD brain. Decreased neuromelanin pigmentation 
in SNc is observed due to the marked loss of dopaminergic neurons. The nigrostriatal pathway degenerates. 
Dauer, W. & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron, 39(6), 889-
909. Reproduced with permission. © 2003 by Cell Press. 
Another characteristic pathology of PD is the formation of α-synuclein protein aggregates 
called Lewy bodies (Schulz-Schaeffer, 2010; Wakabayashi et al., 2013). Research has 
suggested that Lewy bodies interfere with dopamine release from pre-synaptic neurons of 
the SN (Schulz-Schaeffer, 2010; Wakabayashi et al., 2013). Lewy pathology is 
hypothesized to progress along a predictable temporal and spatial pattern, giving rise to 
the Braak staging system for the clinical course of PD (Braak et al., 2003). Studies in PD 
and dementia patients have also linked Lewy body pathology to mild cognitive 
impairment and dementia (Irwin et al., 2012; Kempster, O’Sullivan, Holton, Revesz, & 
Lees, 2010; Selikhova et al., 2009).  
8 
 
Aside from a small percentage of cases for which the risk of developing PD is genetically 
inherited, the vast majority of PD is of idiopathic origin (Dauer & Przedborski, 2003). 
Research has suggested the influence of PD-related genes, environmental neurotoxins, 
and endogenous toxins generated by altered metabolism as potential factors contributing 
to the onset of PD neurodegeneration (Dauer & Przedborski, 2003). However, no single 
explanatory model exists for the etiology of PD. The characteristic motor symptoms of 
PD are largely attributed to the loss of dopaminergic innervation to the DS as a result of 
neurodegeneration of the SNc (Jankovic, 2008). However, the integrity of the VTA is 
largely intact until late stages of disease progression (Kish, Shannak, & Hornykiewicz, 
1988; Rakshi et al., 1999). As a result, VTA dopamine production and downstream VS 
functioning is relatively spared in PD (Kish et al., 1988; Rakshi et al., 1999). 
1.2 Dopaminergic medications 
1.2.1 L-dopa 
Although no therapies to stop or slow down PD disease progression exist, 
pharmacological treatments can alleviate motor symptoms. The most commonly used 
dopaminergic medication is L-3,4-dihydroxyphenylalanine (L-dopa or levodopa; 
Connolly & Lang, 2014). L-dopa is taken orally and acts as a precursor for dopamine 
production (Lang & Lees, 2002). Because L-dopa is subject to degradation in the 
bloodstream, it is almost always co-administered with carbidopa, a dopamine 
decarboxylase inhibitor that prevents premature degradation. Once L-dopa crosses the 
blood-brain barrier, it is metabolized into dopamine by the enzyme aromatic amino acid 
decarboxylase (Meyer & Quenzer, 2013). As such, treating with L-dopa acts as an 
exogenous source of dopamine for PD patients, who are unable to produce the required 
concentrations from the SNc.  
Although L-dopa is initially effective at improving motor functioning, approximately 
50% of PD patients on L-dopa therapy begin to experience motor fluctuations within 4-6 
years (Ahlskog & Muenter, 2001). Dyskinesia, which can be described as involuntary 
non-rhythmic motions, is one such motor disruption (Connolly & Lang, 2014). Because 
dyskinesia results in unintended jerky or swaying movements, PD patients can experience 
9 
 
substantial social embarrassment and stigma (Connolly & Lang, 2014). The onset of 
dyskinesia is strongly correlated with the peak in L-dopa concentration (Obeso, Olanow, 
& Nutt, 2000). Unfortunately, because PD patients often take larger and more closely-
spaced doses of L-dopa as the disease progresses, the risk of dyskinesia increases (Obeso 
et al., 2000). Late PD patients also commonly experience on-off fluctuations, which 
involve a rapid loss of motor functioning as the L-dopa wears off (Blandini & Armentero, 
2014). The presence of these motor disturbances has been found to correlate with the 
duration and dose of L-dopa therapy (Ahlskog & Muenter, 2001). As such, it is 
preferable to avoid the initiation of L-dopa treatment if possible, within the limits of 
patient comfort and quality of life (Ahlskog & Muenter, 2001). 
1.2.2 Dopamine agonists 
DA agonists, another common class of dopaminergic treatment, bind directly to 
dopamine receptors and upregulate post-synaptic receptor activity (Blandini & 
Armentero, 2014). Dopamine agonists can be divided into the first generation ergot-based 
agonists (e.g., bromocriptine, cabergoline, pergolide), and newer non-ergot agonists (e.g., 
pramipexole and ropinirole; Borovac, 2016). Both classes of dopamine agonists target D2 
receptors. However, one of the issues with ergot-based agonists is that they do not bind to 
D2 receptors with high affinity (Borovac, 2016). Ergotine agonists can bind with D1 
receptors, as well as serotonergic and adrenergic receptors, causing a range of adverse 
side effects (Borovac, 2016). In particular, ergot-based dopamine agonists have been 
associated with an increased risk of cardiac and valvular fibrosis (Blandini & Armentero, 
2014). The newer non-ergot agonists have higher affinity with D2 receptors and elicit 
fewer adverse side effects (Borovac, 2016). For these reasons, non-ergot dopamine 
agonists such as pramipexole and ropinirole are much more commonly prescribed for the 
treatment of PD (Connolly & Lang, 2014). When dopamine agonists were first 
introduced for the treatment of PD, they were incorporated into medication regimens as 
an adjunct therapy for L-dopa (Fischer, 1995). With the addition of dopamine agonists, 
PD patients required 20-30% less L-dopa, decreasing the risk and severity of L-dopa-
related motor complications (Brooks, 2000). Dopamine agonists are now commonly used 
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as a monotherapy, especially for early-onset PD patients, for whom it is advisable to 
delay the initiation of L-dopa treatment (Brooks, 2000). 
However, dopamine agonists in particular have been linked to the development of 
impulse control disorders (ICDs; see Section 1.4 for more details). Further, age has been 
found to be negatively correlated with ICD risk (Voon et al., 2007; Weintraub et al., 
2010). Voon and colleagues (2007) found that PD patients with history of pathological 
gambling were significantly younger than a control group of non-ICD PD patients. In a 
large-scale study of 3090 PD patients, younger age was also identified as a risk factor for 
developing an ICD, along with the use of dopamine agonist medication (Weintraub et al., 
2010).  As such, it is crucial to assess pre-existing risk of ICD before incorporating a 
dopamine agonist into a patient’s medication regimen. Each medication is associated with 
unique advantages and disadvantages; the development of a medication regimen that is 
best suited for each individual PD patient is often a delicate balancing act between 
different therapies. 
1.3 Dopamine overdose hypothesis 
L-dopa and dopamine agonists as described above are prescribed by physicians to remedy 
the motor symptoms of PD. However, because of the asymmetrical nature of SNc and 
VTA degradation, treatment with dopaminergic therapies affect DS- and VS-mediated 
functions differently (Vaillancourt, Schonfeld, Kwak, Bohnen, & Seidler, 2013). 
Although dopaminergic treatment has clear benefits for motor ability, its impact on 
cognitive functioning is more complex. Dopaminergic therapy has been shown to 
improve some cognitive functions but impair others (MacDonald & Monchi, 2011). The 
dopamine overdose hypothesis has been proposed to explain this phenomenon 
(Vaillancourt et al., 2013). 
The dopamine overdose hypothesis originates from research in the late 1980s showing 
that the treatment of L-dopa in PD patients can benefit or worsen aspects of frontal 
cognitive function (Gotham, Brown, & Marsden, 1986, 1988). Since then, the hypothesis 
has gained support from behavioural, neuroimaging, and animal research (MacDonald & 
Monchi, 2011). The dopamine overdose hypothesis posits that as dopaminergic 
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treatments remediate dopamine insufficiency in the DS, an unintentional overdosing of 
the VS occurs and other brain regions receiving dopamine from the VTA, which 
maintains relatively normal dopamine levels in PD (Vaillancourt et al., 2013). 
Functioning of dopaminergic structures has been modelled in the shape of an inverse-U 
curve (see Figure 4). Because the DS is dopamine-deficient in PD, it falls left of peak 
performance on the inverse-U curve (Vaillancourt et al., 2013). Functions mediated by 
VS as well as by prefrontal and limbic cortex are already at peak on the curve because of 
intact VTA dopamine production (Kish et al., 1988; Rakshi et al., 1999). Dopaminergic 
medication brings DS functioning to a maximal level, but also pushes VS functioning 
past the peak to a lower level of function (Vaillancourt et al., 2013). This phenomenon 
can be influenced by disease duration, medication dosage, and genetic factors (Cools, 
2006). 
In accordance with the dopamine overdose hypothesis, cognitive functions that have been 
shown to be DS-mediated through neuroimaging and lesion studies largely improve with 
dopaminergic medication. These include selective attention, memory retrieval, decision 
making, task switching, and particularly inhibiting prepotent or habitual responding 
(MacDonald & Monchi, 2011). Conversely, functions that are suggested by 
neuroimaging to be VS-mediated typically show a worsening of performance with the 
addition of dopaminergic treatment. Implicit and explicit learning, reversal learning, 
orienting to stimuli, and cognitive impulsivity all show this expected pattern (MacDonald 
& Monchi, 2011). Behavioural studies commonly use these established patterns of 
behaviour to theorize the neurological basis of the cognitive function of interest (i.e., DS- 
versus VTA-innervated brain region- mediated; MacDonald & Monchi, 2011). 
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Figure 4. The dopamine overdose hypothesis.  
If baseline dopamine level is low (shown in red), L-dopa will improve performance. However, if baseline 
dopamine level is high (shown in blue), L-dopa will worsen performance by pushing performance past the 
maximal level. Vaillancourt, D. E., Schonfeld, D., Kwak, Y., Bohnen, N. I., & Seidler, R. (2013). 
Dopamine overdose hypothesis: Evidence and clinical implications. Movement Disorders, 28(14), 1920-
1929. Reproduced with permission. © 2017 John Wiley & Sons, Inc. 
1.3.1 Mechanisms 
The mechanisms for the dopamine overdose hypothesis are rooted in the unique 
neurobiological properties of the DS and VS. The DS contains MSNs with more and 
denser dendritic projections that allow for rapid maximal response to dopamine 
(Wickens, Budd, Hyland, & Arbuthnott, 2007; Zhang et al., 2009). The DS is also rich in 
DAT, allowing for rapid synaptic clearance, resulting in dopamine activation patterns in 
this region that summate and rapidly decay (MacDonald & Monchi, 2011). When 
dopaminergic therapies are administered in PD, this maximal rapid receptor stimulation is 
remediated in the dopamine-deficient DS (MacDonald & Monchi, 2011). Because of the 
characteristics of DS dopamine signaling, the DS has been theorized to summate inputs 
from many sources and mediate binary responding (i.e., engage or suppress) between 
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alternative choices (MacDonald & Monchi, 2011). As such, the DS has been linked to 
decision-making and selection between stimuli (MacDonald & Monchi, 2011). 
Compared to DS neuroanatomy, the VS is comprised of smaller MSNs with fewer and 
sparser dendritic projections (Wickens et al., 2007). Lower DAT concentration can also 
be found throughout the VS, leading to prolonged synaptic presence of dopamine 
(Wickens et al., 2007). These properties contribute to dopamine signaling patterns in the 
VS that are slower, graded and variable in intensity, and longer lasting (Zhang et al., 
2009). These properties allow the VS to be a suitable mediator of generating associations 
between stimuli and rewards across time, as well processing response outcomes in 
probabilistic events (MacDonald & Monchi, 2011). Indeed, the presence of reciprocal 
connections between VS and memory- and association-related regions of the brain such 
as the anterior cingulate cortex, orbitofrontal cortex, and hippocampus, support the 
interpretation of VS involvement in learning and memory (MacDonald & Monchi, 2011). 
Whereas dopaminergic treatment enhances rapid absolute dopamine signaling in the DS, 
excess dopamine concentration disrupts delicate phasic dopaminergic signaling patterns 
in the VS, leading to impairments in VS-mediated cognitive functions such as associative 
learning (MacDonald & Monchi, 2011). 
1.4 Impulsivity 
The influence of dopamine on impulse control has been a point of scientific interest since 
the idea of dopamine’s role in cognition was recognized. One of the earliest accounts of 
impaired impulse control in PD originated from a group of German researchers who 
presented two case studies of PD patients being treated with dopaminergic therapies who 
experienced strong sexual urges and engaged in sexual delinquency (Berger, Mehrhoff, 
Beier, & Meinck, 2003). Driver-Dunckley, Samanta, and Stacy (2003) then described 
nine PD patients who developed pathological gambling after beginning dopamine agonist 
treatment. The following year, Avanzi, Uber, and Bonfà (2004) published a paper 
discussing two cases of pathological gambling in PD patients who were taking 
dopaminergic replacement therapy. These papers paved the way for the popularization of 
PD-impulse control research in subsequent years (Dodd et al., 2005; Silver, 2005; 
Stocchi, 2005; Weintraub et al., 2006). 
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In the present-day literature, it is commonly known that dopaminergic treatment, in 
particular dopamine agonists, increase risk of developing ICDs. Weintraub and 
colleagues (2010) in a large-scale study of 3090 PD patients found that as many as 13.6% 
of PD patients experienced one or more ICD behavioural symptoms. These problem 
behaviours include pathological gambling, hypersexuality and sex addiction, compulsive 
buying, and binge eating disorder (Weintraub et al., 2010). ICDs often present with 
similar characteristics as drug addiction, such as tolerance effects and/or withdrawal 
symptoms (Leeman & Potenza, 2012). Neuroimaging studies in PD patients with and 
without ICD(s) have found increased dopamine release to the VS in PD subjects with 
concurrent ICD compared to PD patients without ICD (O’Sullivan et al., 2011; Steeves et 
al., 2009; Wu et al., 2015), demonstrating a clear link between the presence of ICDs and 
dysfunctional mesolimbic activation.  
DA agonists were identified as a significant ICD risk factor, having been associated with 
almost three-fold increased odds of developing one or more ICDs, compared to PD 
patients not treated with dopamine agonists (Weintraub et al., 2010). However, L-dopa 
use can also precipitate ICDs, and in fact PD patients with ICDs tend to require higher L-
dopa dosage (Voon, Sohr, et al., 2010). It is standard practice for neurologists to warn PD 
patients of the risk of developing ICDs and to be vigilant for new ICD behaviours when 
starting dopaminergic treatment and especially dopamine agonist therapy (Connolly & 
Lang, 2014). This is particularly critical for PD patients who already have underlying 
obsessive-compulsive tendencies, addictive personalities, or history of addiction (Weiss 
& Marsh, 2012). For these individuals, dopamine agonist treatment might be advised 
against altogether, despite potential motor benefits. ICDs can have serious ramifications 
for quality of life. Anecdotal accounts have been described of PD patients who have 
gambled their life savings away and lost their home in the process, engaged in sexually 
deviant behaviours and ruined their marriage, or developed obesity due to continued 
binge-eating. These dangerous real-life ramifications highlight the importance of 
maintaining appropriate impulse control abilities for everyday function. 
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1.4.1 Multifaceted nature of impulsivity 
Although it is tempting to view impulsivity as a single concept for the sake of simplicity, 
impulsivity has been increasingly understood as a multifaceted construct (Antonelli, Ray, 
& Strafella, 2011). Nombela, Rittman, Robbins, and Rowe (2014) used a factor analysis 
approach to compare different behavioural measures under the umbrella of “impulsivity”. 
They identified four main impulsivity factors: 1) response conflict, interference effects, 
and self-reported impulsivity; 2) motor inhibitory control; 3) time estimation and delay 
aversion; and 4) temporal discounting and reflection impulsivity (Nombela et al., 2014). 
Another research group has suggested a simpler model of motivational/cognitive 
impulsivity and performance/motor impulsivity (Antonelli et al., 2011). Cognitive 
impulsivity corresponds with behaviours including risky decision-making, increased 
propensity towards reward-seeking, and impoverished feedback-learning (Antonelli et al., 
2011). Cognitive impulsivity is purportedly the underlying factor for the development of 
ICDs (Claassen et al., 2011). On the other hand, motor impulsivity refers to the inability 
to withhold automatic and pre-potent responses and impaired ability to cancel responses 
that have already been planned or initiated (Antonelli et al., 2011). Motor impulsivity can 
also impact quality of life, as it has been linked with greater risk of falls (Wylie et al., 
2012). Collectively, cognitive and motor impulsivity comprise aspects of cognition that 
are of clinical relevance in PD.  
1.4.1.1 Cognitive impulsivity 
Because of the link between cognitive impulsivity and ICDs, cognitive impulsivity in PD 
has been a point of clinical interest for researchers. Antonelli and colleagues (2011) 
describe cognitive impulsivity as a complex psychological domain comprised of altered 
decision-making, elevated risk-taking under stable or unknown probabilistic 
contingencies, poor ability to delay rewards in lieu of smaller immediate rewards, and 
impaired reward and reversal learning. Using tasks aimed at assessing cognitive 
impulsivity such as the Iowa Gambling Task, Cambridge Gambling Task, and Risk Task, 
imaging studies have implicated mesolimbic and mesocortical structures including the 
VTA, NAcc, amygdala, and inferior, orbital, and dorsolateral prefrontal cortices (Hsu, 
Bhatt, Adolphs, Tranel, & Camerer, 2005; Rogers et al., 1999; Verdejo-García & 
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Bechara, 2009). The same regions have been implicated in PD patients with concurrent 
pathological gambling (van Eimeren et al., 2010).  
Another popular behavioural paradigm for assessing cognitive impulsivity is the Balloon 
Analogue Risk Task (BART; Lejuez et al., 2002). This task, which is typically 
administered in the form of a computer program, consists of a series of balloons that the 
participant is presented with. For each trial, the participant can choose to pump the 
balloon larger with air by making a keypress response. With each pump, an amount of 
money is accrued for the balloon. Once the participant is satisfied, he/she can press a key 
to collect the accrued money into a permanent bank and move onto the next trial. 
However, if the balloon is over-pumped, the balloon pops and all money is lost for that 
trial. Typically, each balloon has a randomly-determined pop point as to avoid systematic 
learned responses. This task is a measure of risk-taking (i.e., how far participants are 
willing to pump up each balloon before collecting at the risk of the balloon popping). The 
BART has shown sound construct validity; it correlates with other measures of sensation 
seeking, impulsivity, and self-reported history of addiction (Lejuez et al., 2002). 
Functional magnetic resonance imaging (MRI) has supported the involvement of the 
mesolimbic and mesocortical pathways in BART performance, with participants showing 
increased neural activation in the VTA, striatum including the NAcc, insular cortex, 
anterior cingulate cortex, and dorsolateral prefrontal cortex during the task (Rao, 
Korczykowski, Pluta, Hoang, & Detre, 2008). 
The BART has been implemented in the PD population to examine differences between 
PD patients and healthy controls (Simioni, Dagher, & Fellows, 2012), and between PD 
patients with and without ICDs while also comparing medication status (Claassen et al., 
2011). Simioni and colleagues (2012) tested PD patients and age-matched healthy adults 
using the BART. They found that as the trials progressed, PD patients made significantly 
riskier choices compared to controls. This finding parallels the observation of higher 
prevalence of ICDs in PD patients compared to the general population (Ceravolo, Frosini, 
Rossi, & Bonuccelli, 2010). The effect described by Simioni and colleagues (2012) 
persisted at a 1.5-3 year follow-up study. Claassen and colleagues (2011) were interested 
in whether PD patients with ICDs and without ICDs differed on BART performance on 
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and off dopamine agonist medication. They found that on medication, the PD group with 
ICD showed greater risk-taking (i.e., cognitive impulsivity) but this was not found for the 
PD group. Further, dopamine agonists increased risk-taking in participants who were 
taking higher doses compared to those taking lower dopamine doses. Taken together, 
these findings suggest that the effect of dopamine agonists on cognitive impulsivity might 
be dose-dependent and interact with other vulnerabilities of the dopaminergic system that 
promote ICD behaviours.  
1.4.1.2 Motor impulsivity 
Motor impulsivity refers to the inability to withhold pre-potent and automatic responses 
(Antonelli et al., 2011). A number of behavioural paradigms have been developed to 
investigate response inhibition and motor impulsivity. One such paradigm is the Stop 
Signal Task (SST; Logan, Van Zandt, Verbruggen, & Wagenmakers, 2014; Verbruggen 
& Logan, 2008). The Stop Signal paradigm requires participants to respond as quickly as 
possible to some stimulus/stimuli (Go trials). However, if they hear an auditory tone (the 
Stop Signal), participants are asked to withhold the response (Stop trials). The Stop 
Signal appears after a variable Stop Signal Delay (SSD) that is typically dynamically 
adapted until participants are able to inhibit their responses with a 50% success rate. The 
latency between the SSD and the mean reaction time on Go trials, or Stop Signal 
Reaction Time (SSRT), is an estimate of the stop process that is activated by presentation 
of the Stop Signal. A longer SSRT is interpreted as worse inhibitory ability whereas 
shorter SSRT reflects better inhibition.  
Studies that have used the SST to assess motor impulsivity in PD generally find that PD 
patients show worse motor inhibition compared to older adult controls (Obeso, 
Wilkinson, Casabona, et al., 2011; Obeso, Wilkinson, & Jahanshahi, 2011; but see 
Vriend et al., 2015). Research groups who examine the effect of dopaminergic 
medication on SST performance in PD patients have not observed medication effects 
(Claassen et al., 2015; Obeso, Wilkinson, & Jahanshahi, 2011). However, an imaging 
study by Ray Li, Yan, Sinha, and Lee (2008) revealed that activity in the caudate 
correlated with shorter SSRTs (i.e., better inhibitory control). This suggests an influence 
of the dopaminergic system on motor inhibition performance on the SSRT. Claassen and 
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colleagues (2015) compared PD patients with concurrent ICD and PD patients without 
ICD on the SST. They found that the PD group with ICD had motor impulse control 
abilities that were just as proficient as the non-ICD group, despite overwhelming 
evidence that PD patients with ICDs have greater cognitive impulsivity (Claassen et al., 
2011; O’Sullivan et al., 2011; Simioni et al., 2012; Steeves et al., 2009; Wu et al., 2015). 
This finding reinforces the important distinction between motor and cognitive 
impulsivity.  
Another simple behavioural paradigm that assesses motor impulsivity is the Go/No-go 
task (Yang, Glizer, Vo, Seergobin, & MacDonald, 2016). The participant is presented 
with a random series of Go and No-go stimuli. For the Go stimulus (e.g., ‘X’), the 
participant is required to make a keypress response (e.g., press the spacebar). Conversely, 
the participant is instructed to withhold any keypress responses for the No-go stimulus 
(e.g., ‘K’). Participants are asked to make their responses as quickly and accurately as 
possible. Importantly, the Go stimulus is presented at a much higher probability than the 
No-go stimulus (e.g., 75% Go, 25% No-go), establishing ‘Go’ as the pre-potent 
automatic response. As such, the number of No-go errors, which refers to trials for which 
the participant was unable to suppress the Go response and erroneously responded to the 
No-go stimulus, acts as a measure of motor impulsivity. Along a parallel line of 
reasoning, the number of Go timeouts, which refers to the trials for which the participant 
failed to make a Go response in time, corresponds to more conservative responding, or 
less motor impulsivity. In summary, greater motor impulsivity can be observed as 
increased No-go errors and/or decreased Go timeouts. Conversely, less motor impulsivity 
corresponds with fewer No-go errors and/or more Go timeouts. Although the Go/No-go 
paradigm is a rather simple task, it constitutes a good measure of motor impulsivity and is 
easy for participants to comprehend. This is especially important when testing an elderly 
clinical population.  
In a study using the Go/No-go task in young healthy adults, Yang and colleagues (2016) 
found that administration of pramipexole, a dopamine agonist, increased Go timeouts. 
However, they did not observe the parallel observation of decreased No-go errors. The 
researchers attributed this to the fewer number of No-go trials (i.e., 25% of trials) and 
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thus less power in statistical analyses. Nonetheless, the presence of increased Go 
Timeouts suggests that dopaminergic treatment results in more considered responding 
(i.e., decreases motor impulsivity). Importantly, reaction times (RTs) were not different 
between medication states, suggesting that the conservative responding was not due to 
general slowing, sleepiness, or impaired motor ability. In the current study, we wanted to 
extend the same task to a clinical PD sample and examine the effect of dopaminergic 
medication.  
1.4.2 Previous Go/No-go studies in PD 
The Go/No-go paradigm has been employed to investigate motor impulsivity and 
response inhibition in PD.  Most studies focused on differences between various 
subgroups of PD (Cohen et al., 2014; Marzinzik et al., 2015; O’Callaghan, Naismith, 
Hodges, Lewis, & Hornberger, 2013; Pessiglione et al., 2005; Peterson et al., 2015).  
Other studies compared PD performance to that of healthy, age-matched controls 
(Cooper, Sagar, Tidswell, & Jordan, 1994; Dujardin et al., 2013; Franz & Miller, 2002; 
Nakashima, Shimoyama, & Takahashi, 1993). However, few studies have sought to 
understand the effect of dopaminergic therapy on motor impulsivity in PD, contrasting 
performance in the on and off dopaminergic states (Antonelli et al., 2014; Farid et al., 
2009; Herz et al., 2014). To this point, studies using the Go/No-go task to investigate 
motor impulsivity in PD have generally failed to reveal significant group or on-off 
differences (Antonelli et al., 2014; Farid et al., 2009; Herz et al., 2014), though most 
included low numbers of participants and potentially were underpowered to detect 
differences.  Further, the Go/No-go procedures in these studies often featured task 
parameters that failed to clearly establish a pre-potent Go response either by having low 
proportions of Go trials or multiple Go and No-go stimuli (Antonelli et al., 2014; Herz et 
al., 2014). Consequently, to our knowledge, this represents the first study to implement a 
straightforward Go/No-go paradigm in which clear Go responses were biased, and in 
which the impact of dopaminergic therapy on PD patients was tested.  
Geffe and colleagues (2016) used a variant of the Go/No-go task to assess implicit 
learning in de novo untreated PD patients on versus off a single dose of L-dopa.  In the 
conditioning phase, a series of stimuli were presented such that one non-target prime 
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stimulus acted as a reliable cue for presentation of the target stimulus in the subsequent 
trial.  During the conditioning phase, participants learned to anticipate that the target 
stimulus would follow a particular non-target prime stimulus. Each conditioning phase 
was followed by a deconditioning phase, during which non-target stimuli and the target 
stimulus were presented randomly.  PD patients off medication and healthy controls were 
found to make more errors in the No-go condition of the deconditioning phase.  This was 
interpreted as evidence that associations between the prime stimulus and the target 
stimulus had been learned in the conditioning phase.  This learning enhanced the 
anticipation that the target stimulus would follow, leading to more No-go responses. 
When PD patients were on medication, they evidenced fewer No-go errors in the 
deconditioning phase.  The authors interpreted this as evidence that association learning 
between prime stimuli and target stimuli had been less well-learned by patients treated 
with dopaminergic therapy.  This finding is consistent with previous research showing 
that dopaminergic therapy impairs learning (Cools, Barker, Sahakian, & Robbins, 2001; 
Cools, Lewis, Clark, Barker, & Robbins, 2007; Gallant, Vo, Seergobin, & MacDonald, 
2016; MacDonald et al., 2011; MacDonald & Monchi, 2011; Swainson et al., 2000; 
Vaillancourt et al., 2013; Vo et al., 2014; Vo, Seergobin, & MacDonald, 2017).  
However, the fact that PD patients performed fewer No-go responses on dopaminergic 
therapy in the deconditioning phase could also be reflective of enhanced motor control.  
Due to the design, either interpretation is possible.  Geffe and colleagues (2016) used 
their variant of the Go/No-go task to investigate implicit learning whereas the current 
study is focused on motor impulsivity and inhibition. Our version of the Go/No-go task is 
designed to establish a strong pre-potent Go response and accordingly acts as a measure 
of motor inhibition.  
1.5 Current study 
Our goal in this study was to elucidate the effect of dopaminergic therapy on motor 
impulsivity in PD.  Toward this end, we tested PD patients on and off dopaminergic 
medication with the Go/No-go paradigm. PD patients took their usual dopaminergic 
therapy as prescribed by their treating neurologist in the ON Session.  For the OFF 
Session, PD patients refrained from their dopaminergic therapy for 12 to 20 hours as 
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detailed in the Methods section. To our knowledge, this represents the first study to 
implement a straightforward Go/No-go paradigm that clearly established the Go response 
as the pre-potent response, in which the impact of dopaminergic therapy in PD patients 
was directly tested with an on-off design.    
Based on this previous research, here, we hypothesized that PD patients would evidence 
more impulsive responding in the off state. We expected that dopaminergic therapy 
would remedy motor impulsivity, resulting in more considered and cautious responding.  
Again, impulsive responding was expected to be indexed by a) lower Go Timeout rate 
and/or b) higher No-go Error rate.  In contrast, more cautious and considered responding 
would be expressed a) higher Go Timeout rate and/or b) lower No-go Error rate, as 
described above.   
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Chapter 2 : Methods 
A version of this chapter has been published (Yang et al., 2018).  
2.1 Participants 
Twenty-seven PD patients (16 males, mean age 67.81 ± 8.64 years) were recruited from 
the University of Western Ontario and Health Sciences North Hospital in Sudbury, 
Ontario. Participants were pre-screened for inclusion and exclusion criteria. All PD 
patients had been previously clinically diagnosed with PD by a licensed neurologist and 
met the UK Brain Bank criteria for a diagnosis of PD (Hughes, Daniel, Kilford, & Lees, 
1992).  Participants were excluded for the following reasons: neurological disorders other 
than PD (e.g., stroke, seizures, dementia, mild cognitive impairment), psychiatric 
disorders other than mild-to-moderate depression [i.e., 29/63 > on Beck Depression 
Inventory (BDI; (Aaron T Beck, Steer, & Brown, 1996))] or anxiety [i.e., 36/63 > on 
Beck Anxiety Inventory (BAI; Beck, Epstein, Brown, & Steer, 1988)], or history of 
alcoholism or drug abuse. Further, PD patients were excluded if they were not treated 
with dopaminergic therapy. Two patients were taking entacapone as an adjunct to L-
dopa. One patient was taking both entacapone and amantadine as adjunctive therapies. 
One patient was taking dopamine agonists alone as primary therapy. The remaining 
patients were taking L-dopa as their primary therapy: either L-dopa alone (N = 15), or L-
dopa in combination with dopamine agonists (N = 8). The data of participants who scored 
below 24 on the Montreal Cognitive Assessment (MoCA) were excluded from analyses. 
One PD patient was excluded for this reason. Finally, participants were excluded if their 
mean RTs or error rates in the Go or No-go conditions fell outside 2.5 standard deviations 
of the Group mean for that Medication Session (i.e., outliers). Four additional PD patients 
were excluded for having data that were deemed outliers. Analyses were completed with 
the data of the remaining 22 PD patients. This study was carried out in accordance with 
the recommendations of the Health Sciences Research Ethics Boards of the University of 
Western Ontario with written informed consent from all subjects. All subjects gave 
written informed consent in accordance with the Declaration of Helsinki (World Medical 
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Association, 2013). The protocol was approved by the Health Sciences Research Ethics 
Boards of the University of Western Ontario (see Appendix A). 
2.2 Apparatus 
The Go/No-go task was conducted on a desktop computer (LG model 73821B-10) using 
the Windows 7 Professional operating system and a 22.0” monitor (LG Flatron 
W2242TQ) running on a resolution of 1600 x 900 pixels.  Participants were seated 
approximately 50 cm away from the screen and used a keyboard (Logitech K120) to 
record their responses. 
2.3 Procedures 
All participants completed two testing sessions on consecutive days at the University of 
Western Ontario or Health Sciences North Hospital. For the OFF Session, PD patients 
were instructed to abstain from taking L-dopa/carbidopa and entacapone for 12-18 hours 
before the start of the session, and dopamine agonists (e.g., pramipexole, ropinirole, 
pergolide) as well as amantadine, rasagiline, and selegiline for 16-20 hours before the 
start of the session. For the ON Session, PD patients were instructed to take all 
dopaminergic medications for PD as prescribed by their treating neurologist. On-off order 
was randomly assigned and counterbalanced. After the exclusion of five PD patients as 
previously described, twelve participants had an on-off medication order and the 
remaining ten participants had an off-on order. All participants were debriefed about the 
details of the study once they completed the second session. Participants were 
compensated for their time and participation. 
2.3.1 Pre-task assessments 
Demographic and clinical data [i.e., age, sex, education, years of education, handedness, 
PD duration, Levodopa Equivalent Dose (LED)] were collected from all participants. PD 
duration refers to the number of years since a diagnosis of PD. LED is a calculation of the 
daily dose of dopaminergic therapy in units of L-dopa equivalents. Calculation of LED 
(mg) for each PD patient was based on the theoretical L-dopa equivalence (Hiebert, 
Seergobin, Vo, Ganjavi, & MacDonald, 2014; Wüllner et al., 2010) as follows: L-dopa 
24 
 
dose (mg) x 1 + L-dopa controlled release (mg) x 0.75 + L-dopa x 0.33 if taking 
entacapone + amantadine (mg) x 0.5 + bromocriptine (mg) x 10 + cabergoline (mg) x 50 
+ pergolide (mg) x 100 + pramipexole (mg) x 67 + rasagiline (mg) x 100 + ropinirole 
(mg) x 16.67 + selegiline (mg) x 10.22.  
Heart rate (HR), systolic blood pressure (BP), and diastolic BP were measured using an 
automated blood pressure monitor (Omron model BP785N) at the beginning and end of 
each testing session.  Participants were also given a self-reported visual analogue scale 
(VAS; see Appendix B) at these two time-points to assess subjective alertness (Bond & 
Lader, 1974).   
To assess baseline cognitive functioning, PD patients completed general cognitive 
assessments in the on state. These general cognitive assessments and questionnaires were 
the American National Adult Reading Test (ANART; see Appendix C), MoCA (see 
Appendix D), and Controlled Oral Word Association Test (COWAT; see Appendix E). 
The ANART is a measure of verbal intelligence that has been adapted for use in North 
America (Grober & Sliwinski, 1991). The MoCA is a validated cognitive screening tool 
used to detect mild cognitive impairment (Nasreddine et al., 2005). The COWAT is used 
to assess verbal and category fluency (Ross et al., 2007). Participants also completed the 
Barratt Impulsiveness Scale (BIS; see Appendix F), Sensation Seeking Scale (SSS; see 
Appendix G), Questionnaire for Impulsive-Compulsive Disorders in PD – Rating Scale 
(QUIP-RS; see Appendix H), and New Freezing of Gait (NFOG; see Appendix I) 
questionnaire. The BIS and SSS are validated questionnaires estimating trait 
impulsiveness (Patton, Stanford, & Barratt, 1995) and sensation-seeking (Zuckerman, 
Eysenck, & Eysenck, 1978), respectively. The QUIP-RS is a valid and reliable measure 
of ICD symptom severity (Weintraub et al., 2012). The NFOG is a questionnaire used to 
assess freezing of gait in PD (Giladi et al., 2000).  
Additionally, all participants completed the BDI, BAI, and Starkstein Apathy Scale 
(SAS; see Appendix J) in both sessions. The BDI, BAI, and SAS are commonly used 
assessments of depression (Beck et al., 1996), anxiety (Beck et al., 1988), and apathy 
(Starkstein et al., 1992) in PD populations. Motor function was assessed on both testing 
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days using the Motor Subscale of the Unified PD Rating Scale (UPDRS; Goetz et al., 
2008; see Appendix K).  
2.3.2 Go/No-go task 
The Go/No-go paradigm is commonly used to assess motor impulsivity. The task consists 
of Go trials and No-go trials. On Go trials, participants were asked to respond by making 
a keypress as quickly as possible when the letter ‘X’, the visual Go signal, was 
presented. On No-go trials, participants were instructed to withhold keypress responses, 
when the letter ‘K’, the visual No-Go signal, was presented. On every trial, either the 
letter ‘X’, the Go signal, or the letter ‘K’, the No-Go signal, appeared in the center of the 
screen. Participants were instructed to press the spacebar for ‘X’ and avoid pressing any 
keys for ‘K’. The visual stimuli were presented for a maximum of 750 milliseconds (ms), 
or until participants responded with a keypress. A blank screen was presented for a 
random duration between 400 and 800 ms during the inter-trial interval. See Figure 5 for 
a schematic of the Go/No-go task. The letter ‘X’ was presented on 75% of trials, and the 
letter ‘K’ was shown in the remaining 25% of trials, in a random order. This ratio of Go 
to No-go trials was intended to establish the Go keypress as the pre-potent response. 
Participants were instructed to make responses as quickly and accurately as possible. On 
each testing day, participants completed a total of 256 trials, organized into 2 blocks of 
128 trials each, with 10 second breaks at the midpoint of each block and for a slightly 
longer break between the two blocks. 
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Figure 5. Schematic of the Go/No-go task. 
A blank screen was displayed for a random period between 400 and 800 ms as the inter-trial interval. Either 
the Go stimulus (‘X’) or No-go stimulus (‘K’) was displayed for a maximum of 750 ms or until response. 
For the Go stimulus, participants were required to press the spacebar as quickly and accurately as they 
could. For the No-go stimulus, no response was required. The Go stimulus was presented 75% of the time 
whereas the No-go stimulus was presented 25% of the time, establishing “Go” as the pre-potent response. 
2.4 Data analysis 
Physiological measures (i.e., HR, Systolic BP, Diastolic BP, and VAS Alertness) were 
compared using 2 x 2 analyses of variance (ANOVAs), with Medication (on vs. off) and 
Time (Pre-Task vs. Post-Task) as within-subject variables. Affective measures (i.e., mean 
BDI, BAI, and SAS scores) were compared between on and off Medication states using 
paired-samples two-tailed t-tests. The dependent measures for the Go/No-go task were a) 
Go RT, comprising the mean RT for responses that occurred prior to the 750 ms deadline, 
b) No-go Error RT, consisting of the mean RT for erroneous responses provided in the 
No-go condition, c) Go Timeout Rate, reflecting the percentage of trials on which 
participants failed to respond prior to the 750 ms deadline, and d) No-go Error Rate, 
denoting the percentage of trials on which participants erroneously made a keypress 
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response in the No-go condition. RTs were calculated as the time in ms between the onset 
of the visual stimuli and the keypress responses. Data values for Go RTs were trimmed if 
they fell more than 2.5 standard deviations from the mean Go RTs in each medication 
state for each participant. The same process was used to trim No-go Error RT values. 
Lower Go Timeout rates and higher No-go Error rates were indicative of greater motor 
impulsivity whereas higher Go Timeout rates and lower No-go Error rates indexed less 
impulsive responding. Go RTs and No-go Error RTs were analyzed using non-parametric 
two-tailed Wilcoxon Signed Ranks Tests, and Go Timeout Rate and No-go Error Rate 
were analyzed using paired-sample two-tailed t-tests, with Bonferroni correction for 
multiple comparisons. Analyses were performed using Excel (Version 2016), IBM SPSS 
Statistics (Version 21), and GraphPad Prism (Version 6). Data were considered 
significant if p < 0.05. 
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Chapter 3 : Results 
A version of this chapter has been published (Yang et al., 2018).  
3.1 Demographic, baseline screening cognitive, affective, 
and physiological measures 
Demographic and cognitive measures are presented for PD patients (see Table 1). All PD 
patients were within 2.5 standard deviations of the group mean for the NFOG, BIS, SSS, 
QUIP-RS ICD, QUIP-RS Total, MoCA, ANART, COWAT FAS, and COWAT Animal. 
UPDRS scores were compared between on and off medication states using a paired-
samples two-tailed t-test. PD patients showed significantly higher UPDRS scores off 
dopaminergic medication compared to on, which was expected (t(21) = 10.139, p < 
0.001).  
Physiological measures, including HR, Systolic BP, Diastolic BP, and VAS Alertness 
were analyzed using 2 x 2 ANOVAs, with Medication (on vs. off) and Time (Pre-Task 
vs. Post-Task) as within-subject variables. HR was significantly higher Pre-Task 
compared to Post-Task (Figure 6 A; F(1,21) = 24.569, MSe = 31.507, p ≤ 0.001). 
Additionally, Systolic BP was significantly higher off compared to on (Figure 6 B; 
F(1,21) = 15.647, MSe = 88.459, p = 0.001). Diastolic BP showed a similar significant 
effect of Medication, with significantly higher Diastolic BP off compared to on 
dopaminergic therapy for PD patients (Figure 6 C; F(1,21) = 11.743, MSe = 36.046, p 
=0.003). For VAS Alertness (Figure 6 D), no significant differences were found across 
Medication and Time (p > 0.05).  
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Variable Value SD 
N 22 - 
Age 66.77 9.15 
Sex 11 males, 11 females - 
Education 15.18 4.11 
Handedness 20 right, 2 left - 
PD duration 5.23 5.71 
LED 626.59 276.31 
UPDRS - ON 17.43 6.25 
              - OFF 21.82 
t(21) = 10.139 
6.06 
p < 0.001 
NFOG 7.86 7.52 
BIS 59.23 8.99 
SSS 11.59 4.74 
QUIP-RS ICD 13.05  8.62  
QUIP-RS Total 24.91  14.70 
MoCA 27.32  1.73  
ANART 122.72  6.46 
COWAT FAS 15.71  5.22 
COWAT Animal 21.23  6.93 
Table 1. Demographic and cognitive measures. 
Average demographic and cognitive measures for non-excluded PD patients. Values are presented as group 
means ± SD unless otherwise listed. All values are in units of the respective questionnaire or task scale. N: 
number of participants; Education (years): number of years of secondary and post-secondary education; PD 
duration (years): number of years since PD diagnosis; LED (mg): Levodopa Equivalent Dose; UPDRS: 
Motor Subscale Score of the Unified PD Rating Scale/56, listed for on and off medication; NFOG: New 
Freezing of Gait Questionnaire/28; BIS: Barratt Impulsiveness Scale/120; SSS: Sensation-Seeking 
Scale/40; QUIP-RS ICD: Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease Rating 
Scale – Impulse-Control Disorders/64; QUIP-RS Total: Questionnaire for Impulsive-Compulsive Disorders 
in Parkinson’s disease Rating Scale – Total score/112; MoCA: Montreal Cognitive Assessment/30; 
ANART: American National Adult Reading Test/135.6; COWAT FAS (number of words): Controlled Oral 
Word Association Test FAS Task; COWAT Animal (number of words): COWAT Animal Task. UPDRS 
scores were significantly higher off medication (p < 0.001). 
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Figure 6. Physiological measures. 
Physiological measures for PD patients (N = 22). Values are presented as group means ± 95% confidence 
interval as per Cousineau (2005). Data were analyzed using two-way ANOVAs. A) HR (beats per minute) 
was significantly higher Pre-Task compared to Post-Task (*** p ≤ 0.001). B) Systolic BP (mmHg) was 
significantly higher for the OFF Session compared to the ON Session (***). C) PD patients had 
significantly higher diastolic BP (mmHg) off medication compared to on (***). D) No differences in VAS 
Alertness were found across Time and Medication (p > 0.05). 
Affective measures (BDI, BAI, and SAS) were compared between on and off medication 
states using paired-samples two-tailed t-tests (Figure 7). For all affective measures, there 
were no significant differences across Medication states (all p > 0.05). 
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Figure 7. Affective measures. 
Affective measures for PD patients (N = 22). Values are presented as group means ± 95% confidence 
interval for repeated measures as per Cousineau (2005). Affective measures were analyzed using paired-
samples two-tailed t-tests. A) PD patients did not significantly differ on the BDI between on and off 
medication states (p > 0.05). B) There was no significant effect of Medication state on the BAI (p > 0.05). 
C) SAS score did not show a significant difference between on and off states (p > 0.05). 
3.2 Go No-go task 
We investigated the effect of Medication (on vs. off) on the dependent measures of mean 
Go RT and No-go Error RT using two-tailed Wilcoxon Signed Ranks Tests, and Go 
Timeout Rate and No-go Error Rate using paired-samples two-tailed t-tests in the Go/No-
go task using the Bonferroni correction. Mean Go RT was not significantly different for 
PD patients on and off dopaminergic medication (Figure 8 A; p > 0.05). No significant 
difference was found between on and off No-go mean RT (Figure 8 B; p > 0.05). PD 
patients on medication had a significantly higher Go Timeout Rate compared to off 
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dopaminergic therapy (Figure 8 C; t(21) = 2.851, p = 0.010) even after applying the 
Bonferonni correction (i.e., α = 0.0125). Examining No-go Error Rate, there were no 
significant effects of Medication (Figure 8 D; p > 0.05). 
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Figure 8. Go/No-go task measures. 
Dependent Go/No-go measures for PD patients (N = 22), on and off dopaminergic medication. Values are 
presented as group means ± 95% confidence interval for repeated-measures as per Cousineau (2005). Go 
RTs and No-go Error RTs were analyzed using non-parametric two-tailed Wilcoxon Signed Ranks Tests, 
and Go Timeout Rate and No-go Error Rate were analyzed using paired-sample two-tailed t-tests, with the 
Bonferroni correction for multiple comparisons. A) Mean Go RT was not significantly different for PD 
patients on and off dopaminergic medication (p > 0.05). B) No-go Error RT did not show a significant 
effect of Medication (p > 0.05). C) PD patients had a significantly higher Go Timeout Rate on 
dopaminergic medication compared to off (** p = 0.010). D) No significant differences were found 
between on and off medication for No-go Error Rate. 
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Chapter 4 : Discussion 
A version of subsections 4.1, 4.2, 4.4, 4.6, and 4.7 of this chapter has been published 
(Yang et al., 2018). 
4.1 Summary of results 
We found that dopaminergic medication increased the Go Timeout rate in PD patients 
compared to their performance off medication. In this way, dopaminergic therapy 
reduced motor impulsivity, inducing a more conservative response pattern for PD 
patients. We did not see a concomitant decrease in No-go errors for patients on relative to 
off dopaminergic treatment, however. A lower No-go Error rate in the on state would also 
signal decreased motor impulsivity in the No-go condition to parallel adoption of a more 
considered response strategy in the Go condition producing more Go Timeouts. To 
engender a pre-potent Go response, there were far fewer No-go trials relative to Go trials, 
however. It is possible that the No-go condition did not have the statistical power to 
reveal No-go error differences between on and off medication states. Although the effect 
of dopaminergic medication on No-go errors did not reach significance, more Go 
Timeouts when on medication corroborates the notion that dopaminergic treatment 
causes more conservative responding. This is despite the fact that for PD patients, 
dopaminergic therapy improves motor function and speeds movements overall. In 
contradistinction to the widely-recognized enhancement of cognitive/motivational 
impulsivity producing ICDs in PD, increased Go Timeouts in the ON Session suggests 
that dopaminergic medications reduce motor impulsivity.  
Comparisons of physiological measures showed that PD patients had lower HR post 
relative to pre Go/No-go Task. This effect of lower HR was fully expected because 
participants were sitting and inactive for the study period and had acclimatized to the 
novelty of the setting. PD patients also had increased systolic and diastolic BP off relative 
to on dopaminergic medication. This was anticipated as L-dopa is known to lower BP 
(Noack, Schroeder, Heusser, & Lipp, 2014). Participants did not show any differences in 
subjective alertness, BDI score, BAI score, or SAS score across ON-OFF Sessions, 
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demonstrating that our Go/No-go findings were not due to changes in alertness or mood 
between the two medication states. 
4.2 Effects of dopaminergic therapy on the Go/No-go task 
There are few studies in the PD literature that have investigated motor impulsivity using 
the Go/No-go in PD patients. Fewer still have investigated the effect of dopaminergic 
therapy on performance though an important and concerning side effect of dopaminergic 
therapy is disordered impulse control. Herz and colleagues (2014) compared Go/No-go 
performance between PD patients with (N = 13) and without (N = 13) dyskinesia, and 
healthy controls (N = 13), with both patient groups being tested on and off dopaminergic 
medication. Herz and colleagues (2014) used a variant of the Go/No-go task that included 
multiple Go responses (i.e., pressing either the left or right key) in addition to the No-go 
response. They did not find a modulation of Go/No-go performance by dopaminergic 
treatment. The added complexity related to multiple Go responses potentially reduced the 
pre-potency of Go relative to No-go, resulting in less difficulty withholding responses in 
the No-go condition. In another study, Farid and colleagues (2009) compared Go/No-go 
performance of PD patients (N = 9) on and off medication relative to healthy controls (N 
= 9) who performed the task only once. They did not find behavioral differences between 
patients ON versus OFF medication, or relative to performance of healthy older controls 
on Go/No-go accuracy or RT. However, with only nine participants in each group, the 
study likely was underpowered statistically to detect true differences if they occurred.  
Further, medication order was not counterbalanced. PD patients were always assessed in 
the OFF-ON order. In this way, and because healthy controls only performed the task 
once, order effects were confounded with medication effects. Antonelli and colleagues 
(2014) contrasted Go/No-go performance of PD patients (N = 7) on and off the dopamine 
agonist pramipexole. They found that administration of pramipexole increased impulsive 
choices on a delayed discounting task ─ their measure of cognitive impulsivity. However, 
no on-off differences were observed on Go/No-go performance ─ their measure of motor 
impulsivity. This study was important in providing evidence that dopaminergic treatment 
affects distinct forms of impulsivity dissimilarly, supporting the idea that impulsivity is 
not a unitary concept, but rather is multifaceted. These results must be viewed with 
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caution, however, considering that due to a sample size of only seven PD patients, this 
study was likely entirely underpowered. Further, the authors’ rendition of the Go/No-go 
task involved presenting Go signals at 60%, and No-go signals at 40%, limiting the pre-
potency of the Go response.  
In the single occasion to our knowledge when on-off differences have been observed, 
these effects are not interpreted with respect to the effects of dopaminergic therapy on 
motor impulsivity or the ability to withhold pre-potent responses. Geffe and colleagues 
(2016) tested a version of the Go/No-go task in PD patients on and off dopaminergic 
therapy though they included an implicit learning component to their study which was in 
fact the focus (Geffe et al., 2016). Geffe and colleagues’ variant of the Go/No-go task 
involved a conditioning phase during which participants were presented with a series of 
stimuli consisting of one of three non-target cues or a target stimulus, such that one cue 
consistently predicted subsequent target presentation in the following trial. In the Go 
block, participants were instructed to make a keypress in response to the target stimulus. 
In the No-go block, participants were required to make keypress responses to all non-
target cues and inhibit the keypress response for target stimuli. In addition, they had a 
deconditioning phase during which no particular non-target cue predicted the target 
stimulus. Geffe and colleagues found that for the No-go condition, PD patients off 
medication and healthy controls showed increased errors in the deconditioning phase, 
which was interpreted as evidence of implicit learning in the conditioning period. 
However, this increase in error rate was not observed for PD patients when on 
medication, which they interpreted as an impairment in implicit learning with the 
addition of dopaminergic medication. Given that dopaminergic therapy is known to 
adversely impact association learning, this interpretation is highly plausible. These effects 
could also be interpreted as evidence that dopaminergic therapy reduces impulsive 
responding (i.e., lower No-go error rate on relative to off dopaminergic therapy). This 
latter account was not articulated by the researchers but remains a possible 
reinterpretation. Overall, due to the many differences between the Go/No-go task used by 
Geffe and colleagues (i.e., conditioning and deconditioning phases, blocked design of Go 
and No-go trials, four stimuli of which one is the target stimulus), straightforward 
inferences regarding the effect of dopaminergic therapy on motor impulse control were 
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precluded. There were substantial differences in task parameters and research goals 
between Geffe and colleague’s (2016) study and ours. However, their results are not at 
odds with our findings. Consequently, to our knowledge, this represents the first study to 
implement a straightforward Go/No-go paradigm in which clear Go responses were 
biased, and in which the impact of dopaminergic therapy on motor impulsivity in PD 
patients was unambiguously tested.  
4.3 Go/No-go performance in PD subgroups 
The Go/No-go paradigm has been employed to investigate impulsivity and response 
inhibition in various subgroups of PD (Cohen et al., 2014; Marzinzik et al., 2015; 
O’Callaghan et al., 2013; Peterson et al., 2015). In a study investigating inhibition and 
dementia in PD, O’Callaghan and colleagues (2013) compared Go/No-go performance of 
PD patients (n = 25), PD with frontotemporal dementia (n = 11), and older controls (n = 
15). The PD group with frontotemporal dementia conducted more No-go errors (i.e., 
more motor impulsivity) than the PD group, which in turn made more No-go errors than 
controls. Using neuroimaging, the authors provide evidence that frontostriatal atrophy 
might contribute to motor impulsivity in PD. Cohen and colleagues (2014) conducted a 
study contrasting PD patients (n = 13), PD patients with freezing of gait (n = 15), and 
older controls (n = 16). PD patients with freezing of gait were observed making more Go 
Timeouts (i.e., less motor impulsivity) than PD patients, suggesting differential motor 
inhibitory abilities depending on freezing of gait status. In another study of motor 
impulse control and freezing of gait, Peterson and colleagues (2015) contrasted PD 
patients with (n = 13) and without (n = 12) freezing of gait using a Go/No-go task. 
Participants were also fitted with inertial sensors to assess gait metrics during normal 
walking and dual-task walking, for which participants completed a concurrent simple 
behavioural task. The researchers found that Go/No-go performance was correlated with 
dual-task interference for only the PD group with freezing of gait, suggesting a link 
between impaired motor inhibition and freezing of gait in PD. Marzinzik and colleagues 
(2015) examined PD patients with mild (n = 11) and advanced (n = 11) motor symptoms, 
PD patients with dementia (n = 11), Alzheimer’s patients (n = 11), and healthy older 
controls (n = 11) on a cued Go/No-go task. PD patients with advanced motor symptoms 
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and dementia committed more Go Timeouts than controls, but the PD with dementia 
group also committed more No-go errors than controls. In the PD group with dementia, 
task performance was low and correlated with disease severity. The authors concluded 
that deficits in PD dementia develop from dysfunctional inhibitory abilities.  
Findings from these studies suggest that different subgroups of PD patients such as those 
with freezing of gait or dementia might have altered motor impulse control as assessed by 
the Go/No-go task. The current study did not separate PD patients by freezing of gait 
status, and the PD participants tested did not have current or history of dementia. Our 
specific aim in this study was to investigate the effect of dopaminergic medication on 
motor impulsivity in a sample of non-demented PD patients. Future investigations of 
motor impulsivity using the Go/No-go task could expand on the differences in motor 
inhibition between subgroups of PD.  
4.4 Other tasks of response inhibition 
Consistent with the notion advanced here that dopaminergic treatment in fact increases 
motor impulse control, Hiebert and colleagues (2014) found that PD patients evidenced 
greater facilitation in the congruent condition of a modified Stroop task when tested off 
dopaminergic therapy relative to the degree of facilitation observed in healthy age-
matched controls. Facilitation was normalized when PD patients were tested on their 
usual dopaminergic therapy. We surmised that enhanced facilitation in the off state arose 
due to more impulsive and less considered responding, which was rectified by usual 
dopaminergic therapy. The current study and those presented above highlight the fact that 
dopaminergic treatment has varied effects on different aspects of impulsivity. These 
studies present evidence that dopaminergic therapy reduces motor impulsivity in contrast 
to the more widely-understood effect of increasing cognitive/motivational impulsivity 
producing ICDs in PD patients. This understanding is important for the clinical approach 
to PD and decisions regarding titration of dopaminergic therapy considering motor as 
well as cognitive symptoms.  
Although SST studies investigating the effect of dopaminergic medication on motor 
impulsivity have not shown effects of medication on SST performance in PD (Claassen et 
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al., 2015; Obeso, Wilkinson, & Jahanshahi, 2011), neuroimaging has linked motor 
impulse control on the SST to caudate activity (Ray Li et al., 2008). Further, the version 
of the SST used by Obeso, Wilkinson, and Jahanshahi (2011) was a conditional SST 
involving interleaved ‘critical’ and ‘non-critical’ trials, denoted by direction of the 
stimulus. For ‘critical’ trials, participants were asked to stop their responses if they heard 
the auditory Stop Signal. For ‘non-critical’ trials, participants were to ignore the Stop 
Signal and complete the response. The interleaved nature of the trials introduces the 
additional factor of conflict resolution, which potentially acted as a confound in their 
study. Claassen and colleagues (2015) employed a traditional SST paradigm without 
multiple conditions. They contrasted SST performance of 12 PD patients with ICD(s) on 
and off dopaminergic medication, 12 PD patients without ICD on and off medication, and 
12 matched healthy controls. With 12 participants in each group, it is entirely possible 
that the study was underpowered to discover potential medication effects. The current 
study aimed to address the common issue of small sample size in motor inhibition studies 
in PD by testing a total of 27 PD patients.  
Our observations in this study are in accordance with previous research on response 
inhibition and/or response withholding in PD generally. In a meta-analysis of the effects 
of dopaminergic medication and PD disease duration on measures of response inhibition, 
Manza and colleagues (2017) found that for studies of response inhibition with PD 
participants on dopaminergic medication, response inhibition deficits were significantly 
correlated with disease duration. The authors examined studies of common measures of 
response inhibition, including the anti-saccade, Stop Signal, Stroop, and Go/No-go tasks. 
PD patients were found to have poorer response inhibition compared to matched healthy 
controls, in agreement with conclusions from another previous meta-analysis (Kudlicka, 
Clare, & Hindle, 2011). For studies with PD patients at earlier disease stages (i.e., < than 
7 years since diagnosis), dopaminergic medication tended to improve the ability to inhibit 
inappropriate responses, resulting in performance that was worse than but approached the 
level of healthy controls (Manza et al., 2017). Conversely, studies with PD patients at 
later disease stages (i.e., > than 7 years since diagnosis) tended to find that dopaminergic 
medication worsened response inhibition compared to the unmedicated state. The current 
study investigated PD patients with an average disease duration of approximately five 
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years (range 1-26 years), comparable to the patient samples in the studies examined by 
Manza and colleagues (2017) in their meta-analysis of PD patients at earlier disease 
stages. Our finding that dopaminergic therapy caused PD patients to enact more cautious 
responding, yielding more Go Timeouts, is entirely in line with the overall observation in 
the PD literature that dopaminergic therapy improves inhibition of inappropriate motor 
responses in PD. 
4.5 Mechanisms of impulsivity 
4.5.1 Cognitive impulsivity 
Several neurophysiological mechanisms have been proposed to explain the link between 
dopaminergic medication and increased cognitive impulsivity. First, as previously 
described, dopaminergic treatment is known to impair response learning (Foerde & 
Shohamy, 2011; MacDonald & Monchi, 2011). Impaired ability to learn from negative 
consequences or loss could contribute to increased risk-taking (Claassen et al., 2011). 
The increase in tonic dopamine levels in response to dopaminergic therapy might 
mitigate the gaps in phasic dopamine activity corresponding to lack of reward or a 
negative consequence (Cools et al., 2001; Guthrie, Myers, & Gluck, 2009; van Eimeren 
et al., 2010). Next, dopaminergic treatment has been suggested to increase response to 
rewarding stimuli (Claassen et al., 2011). Increased tonic dopamine signaling in the VS 
(especially the NAcc) could amplify the bursts of dopamine activity corresponding to 
rewards (Cools et al., 2001). This interpretation could also be caused by increased 
attentional focus on rewarding experiences, or amplified downstream subjective appraisal 
of rewarding stimuli (Cools et al., 2001; Voon, Reynolds, et al., 2010). Lastly, an 
alternative account suggests that chronic dopaminergic treatment results in a blunted 
response to rewards, leading to increased reward-seeking to compensate for the 
dampened sensation of reward (Riba, Krämer, Heldmann, Richter, & Münte, 2008). 
Consistent with this explanation, PD patients with ICDs have been shown to have lower 
DAT density in the VS compared to non-ICD PD patients (Cilia et al., 2010; Cilia & van 
Eimeren, 2011). Less dopamine synaptic clearance by DAT decreases the dopamine 
receptor availability for phasic responses to rewarding stimuli (Cilia et al., 2010; Mata, 
Hau, Papassotiropoulos, & Hertwig, 2012). It is unclear which one of these explanations 
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best accounts for dopamine-related increased cognitive impulsivity and subsequent ICD 
development; all three explanations likely contribute to this phenomenon. Additional 
theoretical framing is required to combine these different interpretations into a single 
explanatory model.   
4.5.2 Motor impulsivity 
Neuroimaging has linked motor impulsivity with activation in the DS, especially in the 
caudate (Ray Li et al., 2008; Zandbelt & Vink, 2010). The mechanism for improved 
motor impulse control with dopaminergic therapy is likely linked to the 
neurophysiological properties of the many dense MSNs in the DS (Wickens et al., 2007; 
Zhang et al., 2009). Dopamine stimulation results in rapid maximal responses in the DS, 
leading to enhanced signaling of motor impulse control related processes. Because the 
DS tends to mediate binary response patterns (i.e., engage or suppress), it does not appear 
to be susceptible to overdosing effects. No studies to date have demonstrated overdosing 
of the DS; administration of dopaminergic treatment seems to simply increase DS-
mediated cognitive functions. This explains the observation of increased motor impulse 
control with dopaminergic medication in young healthy adults (Yang et al., 2016), who 
presumably have normal dopamine production at baseline. 
The notion of motor impulse control being mediated by DS activity is entirely consistent 
with our findings in the present study. When PD patients are off medication, the SNc is 
unable to supply sufficient dopamine to the DS. Lower motor impulse control abilities 
manifest as greater motor impulsivity on a motor inhibition task such as the Go/No-go 
task. When the patients remediate dopamine-deficiency in the DS using dopaminergic 
medication, motor impulse control is improved, leading to more conservative responding 
(i.e., increased Go Timeouts) on the Go/No-go task. 
4.6 Effects of dopaminergic therapy on cognition 
It is now understood that dopaminergic treatment in PD leads to improvements in some 
aspects of cognition, but impairments in others (Cools et al., 2001; MacDonald et al., 
2011; MacDonald & Monchi, 2011; Rowe et al., 2008). These complex cognitive effects 
are explained by differences in dopaminergic levels at baseline across different brain 
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regions in PD. According to this view, dopaminergic therapy is titrated to a dose needed 
to replenish the dopamine-deficient DS and improve movement symptoms in PD. 
Dopaminergic therapy distributes in a non-targeted fashion, however, overdosing regions 
such as the VS and medial prefrontal regions that are at baseline dopamine-replete, 
innervated by the relatively-spared VTA (Cools, 2006; Cools et al., 2001; Gotham et al., 
1986, 1988; Swainson et al., 2000; Vaillancourt et al., 2013). As a result, DS-mediated 
cognitive functions such as selective attention (Baunez & Robbins, 1999; de Manzano et 
al., 2013; MacDonald et al., 2011), decision-making (Balleine, Delgado, & Hikosaka, 
2007; Hiebert, Vo, et al., 2014; MacDonald et al., 2011), response inhibition (MacDonald 
& Monchi, 2011; Wylie et al., 2012; Zandbelt & Vink, 2010), and overriding pre-potent 
and automatic responses to enact more considered and accurate responding (Ali, Green, 
Kherif, Devlin, & Price, 2009; MacDonald et al., 2014; MacDonald et al., 2011; 
Robertson, Hiebert, Seergobin, Owen, & MacDonald, 2015) show improvements with the 
addition of dopaminergic treatment. This is entirely in line with our findings here in the 
Go/No-go task. In contrast, cognitive functions mediated by brain regions receiving 
dopamine from VTA such as reward processing and feedback learning (Cools et al., 
2001, 2007; Gallant et al., 2016; MacDonald & Monchi, 2011; MacDonald et al., 2013; 
Swainson et al., 2000; Vaillancourt et al., 2013; Vo et al., 2014; Vo et al., 2017), 
motivation (Humphries & Prescott, 2010; MacDonald & Monchi, 2011; Simões-Franklin, 
Hester, Shpaner, Foxe, & Garavan, 2010), and orienting (Anderson et al., 2016; Esslinger 
et al., 2013; Jensen et al., 2007; MacDonald & Monchi, 2011; Zink, Pagnoni, Martin, 
Dhamala, & Berns, 2003) are impaired.  
Both our findings in the Go/No-go task, clarifying the effect of dopaminergic therapy on 
motor impulsivity in PD, and the effects of dopaminergic medication on 
cognitive/motivational impulsivity producing ICDs can be understood through the 
framework provided above. DS has been implicated in limiting motor impulsivity by 
ensuring more considered and less habitual responding (Cools, Rogers, Barker, & 
Robbins, 2010; Djamshidian, O’Sullivan, Lees, & Averbeck, 2011; Hood et al., 2007; 
MacDonald et al., 2011; Ness & Beste, 2013; Robertson et al., 2015). In contrast, VTA-
innervated brain regions such as VS and orbitofrontal cortex mediate motivation and 
reward processing (Balleine et al., 2007; Drijgers et al., 2012; Rowe et al., 2008). In PD, 
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dopaminergic therapy normalizes DS dopamine deficiency and therefore predictably 
improves the ability to make deliberate and less impulsive responses as we see here 
(Balleine et al., 2007; Drijgers et al., 2012; Rowe et al., 2008). Conversely, treatment 
with dopaminergic agents overdoses VS and other VTA-innervated brain areas, 
dysregulating motivation and impairing reward processing, leading to ICDs. Our findings 
and the literature linking ICDs to dopaminergic therapy are easily reconciled, 
understanding that impulsivity is a multifaceted concept, with its various forms mediated 
by distinct brain regions that are differentially dopamine-depleted in PD and hence 
dissimilarly affected by dopaminergic therapy.  
4.7 Limitations 
By not presenting baseline PD performance relative to that of controls, we have not 
established abnormal control of motor responses (i.e., motor impulsivity) in the PD 
patients in our study. This was not our aim, though, as detailed above, reviews of this 
literature confirm that PD patients consistently exhibit deficits in inhibition of pre-potent 
responses and motor impulsivity (Kudlicka et al., 2011; Manza et al., 2017). Our 
objective was to explicitly investigate, in back-to-back tests within PD patients, the effect 
of dopaminergic therapy on motor impulse control using an accepted measure of this 
process (i.e., Go/No-go; Antonelli et al., 2014; Hamidovic, Kang, & de Wit, 2008; Rubia 
et al., 2001). Here, in PD patients, we entirely replicated the pattern that we observed in 
healthy young controls (Yang et al., 2016). Specifically, we previously showed that 
dopaminergic therapy increases the Go Timeout rate in healthy young controls. We 
previously interpreted this pattern of results, as we have here, as evidence that 
dopaminergic therapy increases control over motor responses and decreases the tendency 
to make more impulsive responses (Yang et al., 2016).  
The alternative explanation that dopaminergic therapy simply slowed cognitive processes 
and/or motor execution rather than specifically promoting a more conservative response 
pattern is contradicted by other measures in our study, in addition to well-studied, 
established effects of dopaminergic therapy on behavior in the wider PD literature. 
Dopaminergic therapy did not affect overall RTs in our PD patients and it significantly 
speeded motor responses assessed with the UPDRS. Addressing bradykinesia and 
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increasing the speed and fluency of movements and motor responses is the chief 
beneficial effect of dopaminergic therapy in PD (Espay et al., 2011; Macerollo et al., 
2016). There is little evidence to suggest that dopaminergic therapy generally slows 
cognitive processes and in fact there is support that it hastens them (Cools et al., 2001; 
Hanna-Pladdy, Pahwa, & Lyons, 2015; Hood et al., 2007; MacDonald et al., 2011; 
MacDonald & Monchi, 2011; Righi, Viggiano, Paganini, Ramat, & Marini, 2007; Shook, 
Franz, Higginson, Wheelock, & Sigvardt, 2005). In contrast, dopaminergic therapy has 
been shown to increase response inhibition abilities as well as to promote the adoption of 
a more conservative response criterion, consistent with our explanation for increased Go 
Timeouts in the on state for PD patients in our study.  
It was also not possible for PD patients to be blinded to their medication status during the 
on-off manipulation in our study. This is because patients had to comply with particular 
instructions to take or abstain from their usual dopaminergic therapy in a certain manner 
for on and off session, respectively. Even if these instructions could be concealed, 
patients are well acquainted with their symptoms both on and off dopaminergic therapy 
which precluded blinding patients to our medication manipulation. Consequently, we 
cannot rule out the possibility that expectancy effects contributed to our results. However, 
as previously noted, dopaminergic medications are known to speed motor functions in 
PD patients (Espay et al., 2011) and consequently any expectancy effects would have 
acted contrarily to the results that we obtained. Overall, despite these acknowledged 
alternative interpretations, we interpret enhanced Go Timeout responses in the on state as 
evidence that dopaminergic therapy reduces motor impulsivity. This account for our 
findings is supported by a larger literature as detailed in the sections above.  
Our finding of more Go Timeouts with the administration of dopaminergic therapy could 
alternatively be interpreted as a worsening of ability to orient to stimuli. Lesion and 
neuroimaging studies have linked orienting to stimuli with the VS (see MacDonald & 
Monchi, 2011 for a review). A reinterpretation of our results in response to dopaminergic 
treatment as poorer ability to orient to stimuli, which is presumably a VS-mediated 
function, is entirely consistent with the patterns described by the dopamine overdose 
hypothesis (Anderson et al., 2016; Esslinger et al., 2013; Jensen et al., 2007; MacDonald 
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& Monchi, 2011; Zink et al., 2003). Here, we explain our finding of increased Go 
Timeouts with the addition of dopaminergic treatment as decreased motor impulsivity 
because the Go/No-go task has largely been interpreted in the context of response 
inhibition and motor impulse control (Antonelli et al., 2014; Ballanger et al., 2009; 
Fillmore, 2003; Liddle, Kiehl, & Smith, 2001; Rubia et al., 2001). However, we are not 
able to fully rule out the possibility of an effect of dopaminergic treatment on the ability 
to orient to stimuli.  
Another limitation of the current study was that we did not conduct functional 
neuroimaging despite interpreting our behavioural results with respect to changes in 
activity in different brain areas. Our conclusions are supported by the wider literature 
implicating the DS in motor impulse control (Ray Li et al., 2008; Zandbelt & Vink, 2010) 
as well as imaging studies that show improvements in DS-mediated cognitive functions 
with the addition of dopaminergic therapy (Ali et al., 2009; MacDonald et al., 2014; 
MacDonald et al., 2011; Robertson et al., 2015; Zandbelt & Vink, 2010). However, the 
interpretation of our behavioural results would have been further strengthened with the 
use of functional neuroimaging to demonstrate the changes that occur in SNc- and VTA-
innervated brain regions on and off dopaminergic therapy. Future investigations could 
incorporate functional MRI and an MRI-compatible version of the Go/No-go task.  
4.8 Conclusions 
Overall, the results of this study lend support for the role of dopaminergic therapy in 
decreasing motor impulsivity in PD. Our findings emphasize that impulsivity should be 
addressed as a multi-faceted construct rather than a single concept. We also highlight the 
importance of examining non-motor functions affected by dopaminergic medication in 
PD. These findings improve our understanding of how dopaminergic therapy affects 
cognition in PD. This knowledge will ultimately aid clinicians in developing optimal 
dopaminergic medication regimens for their PD patients, taking into account the different 
impacts on cognitive as well as motor functioning. 
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Appendix K. Unified PD Rating Scale - Motor Subscale (UPDRS). 
 
UPDRS Protocol 
Ask at the start “which arm/hand do you have most difficulty with?” 
Always start with LESS impaired side 
Only model for a few seconds, then stop 
 
“This is subject (PD/CTRL #), session #, (on/off) medication.” 
1. Film face at rest for a few seconds 
2. Ask patient to speak one-two sentences (for dysarthria) 
• “Today is a very nice day outside” 
• “I am at the University for an experiment” 
3. Evaluate resting tremor  
a. hands relaxed on thighs 
b. with cognitive stressing “Close your eyes and name the months of the year 
backward from December” 
4. Evaluate tone 
a. Bilateral upper extremities 
5. Evaluate postural tremor  
a. hands outstretched 
b. fingertips apposed (forming wings with arms ensuring fingers are not touching) 
6. Evaluate action tremor  
a. Finger-to-nose (finger target should be arms-length away and in same position) 
7. Evaluate bradykinesia 
a. Finger taps (pinching) “Big and fast” 
b. Hand opening-closing movements “Big and fast” 
c. Pronation-supination movements “Fast as you can” 
d. Toe-tapping  (minimum 3 inches off ground) 
8. Ask patient to rise from the chair without the assistance of his/her arms (arms crossed 
over chest) “Fold your arms across and chest and stand up” 
9. Evaluate gait, ask to walk up and down hallway 2-3 times, with turns 
10. Pull test “Try to maintain your balance and limit yourself to one step backwards” 
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